BioNexus Gene Lab Corp Common stock Total Liabilities
BioNexus Gene Lab Corp Common stock total liabilities. Based on the latest financial reports, BioNexus Gene Lab Corp Common stock (BGLC) has total liabilities worth $804.97K USD as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check BGLC asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of BioNexus Gene Lab Corp Common stock (2016–2024)
Total liabilities of BioNexus Gene Lab Corp Common stock from 2016 to 2024. This chart illustrates how BioNexus Gene Lab Corp Common stock's total liabilities have evolved over time, based on quarterly financial data. Explore BGLC long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
BioNexus Gene Lab Corp Common stock Competitors by Total Liabilities
The table below lists competitors of BioNexus Gene Lab Corp Common stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
JPMorgan China Growth & Income PLC
LSE:JCGI
|
UK | GBX4.06 Million |
|
Laxmi Cotspin Limited
NSE:LAXMICOT
|
India | Rs531.88 Million |
|
The Income & Growth VCT
LSE:IGV
|
UK | GBX347.63K |
|
Cyclerion Therapeutics Inc
NASDAQ:CYCN
|
USA | $1.84 Million |
|
Invion Ltd
AU:IVX
|
Australia | AU$1.24 Million |
|
Brown Advisory US Smaller Companies PLC
LSE:BASC
|
UK | GBX1.55 Million |
|
Majedie Investments
LSE:MAJE
|
UK | GBX813.00K |
|
Catheter Precision Inc.
NYSE MKT:VTAK
|
USA | $9.21 Million |
Liability Composition Analysis (2016–2024)
This chart breaks down BioNexus Gene Lab Corp Common stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is BioNexus Gene Lab Corp Common stock's balance sheet.
Liquidity & Leverage Metrics
BioNexus Gene Lab Corp Common stock Total Liabilities Ratios Explained
BioNexus Gene Lab Corp Common stock total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.30 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.12 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how BioNexus Gene Lab Corp Common stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for BioNexus Gene Lab Corp Common stock (2016–2024)
The table below shows the annual total liabilities of BioNexus Gene Lab Corp Common stock from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $2.11 Million | +21.19% |
| 2023-12-31 | $1.74 Million | -16.06% |
| 2022-12-31 | $2.08 Million | -13.34% |
| 2021-12-31 | $2.39 Million | -30.65% |
| 2020-12-31 | $3.45 Million | +3071.74% |
| 2019-12-31 | $108.87K | -16.45% |
| 2018-12-31 | $130.31K | -88.94% |
| 2017-12-31 | $1.18 Million | +88026.70% |
| 2016-12-31 | $1.34K | -- |
About BioNexus Gene Lab Corp Common stock
BioNexus Gene Lab Corp., through its subsidiaries, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic products in Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. The company operates through three segments: Trading of Industrial Chemicals; Provision for Genomic Screening Services; a… Read more